ASTRAZENECA PLC

CIK 901832 · last filed 2021-03-16

ASTRAZENECA PLC is a corporate insider who has filed 5 SEC Form 4 insider transactions across 4 companies since 2014. The most recent filing, for VIE, was dated Mar 16, 2021. Across all open-market trades the lifetime net is −$82.0M, making them a net seller over the disclosed history. The firm reports its address in Cambridge. 38 SEC filings were submitted jointly with ALEXION PHARMACEUTICALS, INC.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Disclosed Exposure

$0

Companies

4

Total Filings

5

Lifetime Open-Market Net

-$82.00M

Filer Profile

Reported Address

1 FRANCIS CRICK AVENUE
CAMBRIDGE BIOMEDICAL CAMPUS
CAMBRIDGE CB2 0AA

Phone

011 44 20 7304 5000

State of Incorporation

United Kingdom

Formerly Known As

ZENECA GROUP PLC (1995–1999)

Related Filers

ALEXION PHARMACEUTICALS, INC. — 38 joint filings, latest 2021-07-14

PFIZER INC — 21 joint filings, latest 2014-05-27

CAPITAL RESEARCH & MANAGEMENT CO — 7 joint filings, latest 2008-02-13

Mani Sharma — 6 joint filings, latest 2026-08-07

AstraZeneca UK LTD — 4 joint filings, latest 2021-03-16

Cellectis S.A. — 3 joint filings, latest 2025-01-24

AB INVESTOR — 2 joint filings, latest 2004-02-17

PALVELLA THERAPEUTICS, INC. — 2 joint filings, latest 2023-02-10

Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.

Symbol	Role	Shares	Price	Disclosed Exposure	Lifetime OM Net	Filings	Latest Filed
Viela Bio, Inc. (VIE) Delisted	10%+ Owner	0	—	—	$0	1	2021-03-16
Entasis Therapeutics Holdings Inc. (ETTX) Delisted	10%+ Owner	2,164,855	$2.19	$4.74M	$7.40M	1	2018-10-02
ALBIREO PHARMA, INC. (ALBO) Delisted	10%+ Owner	508,141	$44.15	$22.43M	-$21.40M	1	2017-12-05
Regulus Therapeutics Inc. (RGLS) Delisted	10%+ Owner	35,417	$8.16	$289.0K	-$68.00M	1	2014-11-14

Recent Filings

5 filings

Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.

Filed	Symbol	Action	Net Shares	Net $	Link
2021-03-16	Viela Bio, Inc. (VIE) Delisted	U	−29,300,668	-$1.55B	EDGAR
2020-02-07	—	Buy (P)	+25,893,800	$0
2018-10-02	Entasis Therapeutics Holdings Inc. (ETTX) Delisted	Mixed	+4,329,702	$7.40M	EDGAR
2017-12-05	ALBIREO PHARMA, INC. (ALBO) Delisted	Sell (S)	−1,000,000	-$21.40M	EDGAR
2014-11-14	Regulus Therapeutics Inc. (RGLS) Delisted	Sell (S)	−4,000,000	-$68.00M	EDGAR

Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.